My background is nuclear engineering and physics ... and there's no place else to go. We're operating blue water operations, so we can't go land somewhere in a runway and we can't land another ...

Cells were isolated using lymphocyte separation medium (Corning Cellgro, Manassas, VA, Cat#: 25-072-CI) and viable cell numbers were calculated using trypan blue. Primary cells ... Total Serine and ...

Amgen’s Lumakras has an accelerated approval for those with KRAS G12C-mutated non-small cell lung cancer and has until 2028 to complete a study to support full approval—a new deadline after ...

His tenure at Amgen included ... with a strong background in hematology and oncology, and he is ideally suited to lead the Commercial team and fortify our global cell therapy leadership position ...

Free cash flow surged to $4.4 billion, up a remarkable 1,367% year over year. Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

Shares of biotech company Amgen (NASDAQ:AMGN) jumped 5.3% in the morning session after the company reported strong fourth-quarter results. Amgen exceeded analysts' revenue expectations this ...

Amgen Inc.'s (NASDAQ:AMGN) dividend will be increasing from last year's payment of the same period to $2.38 on 7th of March. This takes the annual payment to 3.1% of the current stock price, which ...

Amgen is a biotechnology leader with competitive advantages in scale, R&D, manufacturing efficiency, and distribution, bolstered by a robust pipeline and rising margins. I currently rate Amgen as ...

Biotechnology specialist Amgen (NASDAQ:AMGN) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS ...

What Happened: Grygiel's recent move involves selling 1,589 shares of Amgen. This information is documented in a Form 4 filing with the U.S. Securities and Exchange Commission on Friday. The total ...

MariTide Phase 3 studies to begin in first half of year FDA places hold on AMG 513 obesity drug trial Amgen's Q4 earnings beat estimates, revenue up 11% Feb 4 (Reuters) - Amgen (AMGN.O), opens new ...

Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with obesity was placed on clinical hold by the U.S. Food and ...